MedTrace Logo

A Double Blind Crossover Trial of Levetiracetam (Keppra®) and Placebo in the Treatment of Restless Legs Syndrome (RLS)

NCT00247364 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2005-11-01

No results posted yet for this study

Summary

To define the effective dose and tolerability of levetiracetam in individuals with Restless Legs Syndrome (RLS). It is hypothesized that levetiracetam will be well tolerated, safe and effective in treating the symptoms of RLS.

Conditions

  • Restless Legs Syndrome

Interventions

DRUG

Levetiracetam (Keppra)

Sponsors & Collaborators

  • UCB Pharma

    collaborator INDUSTRY

  • Sleep Health Centers

    lead OTHER

Principal Investigators

  • John W Winkelman, MD, PhD · Sleep Health Centers, Brigham and Women's Hosptial

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Completion
2005-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00247364 on ClinicalTrials.gov